| 0.215 0.006 (2.87%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.36 | 1-year : | 0.45 |
| Resists | First : | 0.31 | Second : | 0.38 |
| Pivot price | 0.21  |
|||
| Supports | First : | 0.18 | Second : | 0.15 |
| MAs | MA(5) : | 0.2 |
MA(20) : | 0.23 |
| MA(100) : | 0.64 |
MA(250) : | 1.36 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.1 |
D(3) : | 15.7 |
| RSI | RSI(14): 34.8 |
|||
| 52-week | High : | 2.98 | Low : | 0.18 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CNSP ] has closed above bottom band by 44.8%. Bollinger Bands are 87.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.22 - 0.22 | 0.22 - 0.22 |
| Low: | 0.2 - 0.2 | 0.2 - 0.2 |
| Close: | 0.21 - 0.21 | 0.21 - 0.22 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Wed, 24 Apr 2024
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024 - The Globe and Mail
Tue, 23 Apr 2024
CNS Pharmaceuticals (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event - The Globe and Mail
Tue, 23 Apr 2024
CNS Pharmaceuticals to Present at the LSX World Congress 2024 - Yahoo Finance
Mon, 22 Apr 2024
CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity - Yahoo Canada Finance
Mon, 01 Apr 2024
CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical ... - Yahoo Finance
Tue, 27 Feb 2024
CNS Pharmaceuticals Strives to Regain Nasdaq Compliance - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 9.53e+006 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 54 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.886e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -159.9 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 17.22 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -10 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.01 |
| Price to Cash Flow | -0.34 |
| Dividend | 0 |
| Forward Dividend | 49980 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|